Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

IV Infusion to Oral Dosing: Conversion Methods

IV Infusion to Oral Dosing: Conversion Methods

The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

One-Compartment Open Model for IV Bolus Administration: General Considerations

One-Compartment Open Model for IV Bolus Administration: General Considerations

The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.

NEJM evidence·2024

Same author

Iron Repletion for Patients with Heart Failure and Kidney Dysfunction.

Clinical journal of the American Society of Nephrology : CJASN·2023

Same author

Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial.

Clinical journal of the American Society of Nephrology : CJASN·2022

Same author

Serum Phosphorus and Pill Burden Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide: One-Year Follow-Up on a Contemporary Cohort.

International journal of nephrology and renovascular disease·2022

Same author

Proactive High-Dose IV Iron Is Preferred Therapy in ESKD Patients: PRO.

Kidney360·2022

Same author

Groundhog Day: research without old data and old references.

Psychological medicine·2022

Search research articles

Related Experiment Video

Updated: May 4, 2026

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes

Published on: July 7, 2023

Update on intravenous iron choices.

Derek S Larson¹, Daniel W Coyne

¹Renal Division, Washington University, St. Louis, Missouri, USA.

Current Opinion in Nephrology and Hypertension

|January 10, 2014

Summary

Newer intravenous iron formulations offer rapid iron repletion for patients with chronic kidney disease (CKD). These advanced iron therapies provide an effective and safe option for managing iron deficiency anemia in CKD.

Area of Science:

Nephrology
Hematology
Pharmacology

Background:

Iron deficiency is a primary driver of anemia in chronic kidney disease (CKD).
Impaired intestinal iron absorption is a common complication in CKD patients.

Purpose of the Study:

Review the pathophysiology of intestinal iron absorption in CKD.
Compare newer intravenous (i.v.) iron agents with established i.v. iron products.

Main Methods:

Literature review of i.v. iron agents.
Comparative analysis of iron binding characteristics, infusion parameters, and safety profiles.

Main Results:

Newer agents (ferumoxytol, ferric carboxymaltose, iron isomaltoside) exhibit avid iron binding, minimizing labile iron release.

More Related Videos

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Published on: February 23, 2024

Related Experiment Videos

Last Updated: May 4, 2026

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes

Published on: July 7, 2023

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Published on: February 23, 2024

Complex carbohydrate shells in newer agents may reduce infusion-related reactions.

Higher single doses of newer i.v. iron agents can be administered safely, often in 15 minutes.

Conclusions:

Newer i.v. iron products enable swift, single-dose iron repletion for deficient patients.
Further research is necessary to fully understand the long-term risks and benefits of these novel i.v. iron therapies.